Paras Biopharmaceuticals Finland Oy was established with the vision of using active synergy of academic expertise with proven industrial experience in bringing commercial scale protein production to market. Paras Biopharmaceuticals Finland Oy aims to bring workable innovative solutions to a range of problems. The business model for Paras Biopharmaceuticals Finland Oy is based on technology development for biosimilars and their out-licensing and work together in collaboration.
In Paras Biopharmaceuticals Finland Oy R&D, we work on the principle –"Why have complications, you can avoid?" Rational design of processes combining academic and industrial expertise means increased efficiency without compromising quality. At Paras, our ultimate objective is to use innovative scientific ideas to make healthcare more affordable.
Paras Biopharmaceuticals Finland Oy is using most efficient production hosts including E. Coli. Sales of proteins produced in prokaryotes e.g. E. Coli have continued to increase. There are several advantages to use E. Coli as host organism.
Paras Biopharmaceuticals Finland Oy has developed a number of products under the following categories:
Paras products are in an advanced stage of development. These include Teriparatide (osteoporosis), Anakinra (rheumatoid arthritis), and Biosimilar Diabetes long acting Insulin (glargine), and a rapid acting Insulin (insulin aspart). There are other products in the Paras pipeline.
Paras Biopharmaceuticals Finland Oy has developed very high yielding and stable clones for the production of recombinant proteins. Paras Biopharmaceuticals Finland Oy utilizes core facilities to carry out electron microscopy studies to establish production of Biosimilars and long therapeutic peptides in recombinant E. Coli strains.
Paras Biopharmaceuticals has developed propriety expression vectors which incorporate a specially designed gene cassette. All genes are individually optimized using the most advanced gene optimization programs available in the world. Paras utilizes the most advanced knowledge to achieve the highest expression codon sequences for genes.
Paras propriety vector consists of unique signal sequences, promoter sequences, suitable spacers, Paras propriety partner sequences, and optimized gene codon sequence for therapeutic protein. Expression vectors also include suitable antibiotic resistance markers for the clone selection.
Recombinant clones are tested for their expression levels, stability and evaluated for highest expression of therapeutic protein targets. All vectors are authenticated by DNA sequencing to ensure the presence of the correct inserts in the vector.
Paras products are extensively characterized and validated. The SDS- PAGE and mass spectrometry analysis of the diabetes product and an osteoporosis product of Paras portfolio is shown below. Full fingerprinting of the protein includes validation of the appropriate primary, secondary and tertiary structures, control and validation of appropriate post translational modification and of quality and consistency of the initial expression through to the final product.
This website uses cookies; by continuing to use this page, you consent to their use. I Understand About Cookies.
